Every serious lifter knows that mTORC1 is the molecular switch for muscle protein synthesis. What almost none of them know is that a specific lipid molecule can activate that same switch through a completely independent pathway — one that does not require mechanical stimulus at all.
Phosphatidic acid sits at the intersection of lipid biochemistry and hypertrophy signalling, and the research has progressed far enough that ignoring it as a serious topic is no longer defensible.
---
Phosphatidic acid (PA) is a phospholipid produced in skeletal muscle by the enzyme phospholipase D (PLD) in response to mechanical stretch. During resistance exercise, membrane deformation activates PLD, which converts phosphatidylcholine into PA. This PA then directly binds to the FKBP12-rapamycin binding (FRB) domain of mTOR, activating the mTORC1 complex and initiating downstream protein synthesis signalling via p70S6K and 4E-BP1.
The critical distinction: PA activates mTOR through the lipid-binding domain, while mechanical tension activates mTOR through integrin-FAK signalling. These are parallel inputs to the same convergent pathway. In theory, supplemental PA could amplify the mTOR signal from training beyond what mechanical load alone produces.
---
Joy et al. (2014) published a randomised controlled pilot trial in the Nutrition and Metabolism journal. Sixteen resistance-trained men were assigned to either 750mg soy-derived PA or placebo for 8 weeks of periodised resistance training. The PA group gained a statistically significant 2.4 kg of lean mass compared to 1.2 kg in the placebo group — a doubling of lean mass accrual over the same training programme.
Strength gains followed a similar pattern: PA group increased leg press by 52% versus 30% in placebo.
These are striking numbers for an 8-week pilot. The sample size is small (n=8 per group), and a pilot is a pilot — but the effect size is large enough to take seriously. Joy et al. noted that the soy-derived PA used (branded as Mediator) had a standardised PA content of 50%, which matters for dose replication.
---
The dose-response question is partially answered by Hoffman et al. (2012), who compared 250mg, 375mg, and 750mg PA supplementation. The 750mg dose produced the largest acute increases in muscle protein synthesis markers, suggesting a threshold effect. Below 500mg, the signal appears insufficient to drive meaningful mTOR activation above training alone.
Timing follows the same logic as any mTOR-activating intervention: PA taken 30–60 minutes pre-training, when PLD is already being activated by mechanical loading, may produce synergistic rather than merely additive mTOR activation.
A second dose strategy — 375mg pre-workout plus 375mg pre-sleep — maintains elevated PA availability during the post-exercise protein synthesis window, though this specific split has not been directly compared to single-dose protocols.
---
The mechanistic framework for PA is more complete than for many popular hypertrophy supplements. The rapamycin studies are illuminating here: rapamycin is an mTOR inhibitor that blocks the FRB domain precisely where PA binds. When muscle cells are treated with rapamycin, PA-induced mTOR activation is completely abolished — providing direct pharmacological evidence that PA's mechanism is FRB-dependent, not some off-target effect.
What remains unclear is the long-term dose-response relationship, the comparative effectiveness across PA sources (soy vs egg vs synthesised), and whether the adaptation response is attenuated in highly trained athletes approaching their genetic ceiling.
---
For natural athletes seeking to optimise every evidence-backed variable in their programme, PA represents one of the few supplement mechanisms with genuine mechanistic plausibility and supporting RCT data — even if that data is limited in scale.
The context matters: PA is not a replacement for training, protein intake, or progressive overload. It is a potential amplifier of an already well-designed programme. Athletes not yet optimising total daily protein, training volume, and sleep will see zero marginal benefit from PA. The foundations come first.
Accurately tracking protein intake targets — and ensuring each meal meets the leucine threshold for mTOR stimulation — remains the non-negotiable prerequisite before any supplement discussion is relevant.
---
The biology of hypertrophy signalling is more nuanced than the bodybuilding community's traditional protein + mechanical tension framework. Lipid second messengers are part of the story, and phosphatidic acid has earned its place in a serious evidence review.
Is phosphatidic acid something your athletes have trialled, and what were the reported outcomes versus expectation?